Research Grade Sozinibercept
一、中文名稱：
Research Grade Sozinibercept，科研級Sozinibercept
二、產(chǎn)品描述
Sozinibercept 在血管生成研究中作用關(guān)鍵。探索腫瘤生長與轉(zhuǎn)移機(jī)制時，它能特異性阻斷 VEGFC、VEGF - D 與 VEGFR - 3 的結(jié)合，抑制腫瘤相關(guān)淋巴管生成。在乳腺癌模型中，使用它可降低腫瘤細(xì)胞通過淋巴管轉(zhuǎn)移的幾率，為腫瘤轉(zhuǎn)移防治策略研究提供依據(jù)。在眼科疾病研究方面，針對濕性年齡相關(guān)性黃斑變性（wAMD）的研究顯示，Sozinibercept 能抑制脈絡(luò)膜新生血管形成，調(diào)節(jié)相關(guān)信號通路，減少新生血管，為 wAMD 治療方法探索提供新方向。在傷口愈合研究中，Sozinibercept 參與調(diào)節(jié)血管新生和重塑。在皮膚創(chuàng)傷模型實驗中，使用它可使傷口處血管生成更有序，促進(jìn)傷口快速愈合，為理解組織修復(fù)機(jī)制提供思路。
三、產(chǎn)品詳情
名稱：Research Grade Sozinibercept，科研級Sozinibercept
貨號：DHE70402
表達(dá)系統(tǒng)：Mammalian Cells
種屬反應(yīng)性：Human
同種型：Vascular Endothelial Growth Factor Receptor 3 fusion protein with IgG1 Fc Fragment.
克隆類型：Monoclonal
靶標(biāo)：Vascular endothelial growth factor C, VEGFC, Flt4-L, VEGF-C, Vascular endothelial growth factor-related protein, VRP, Flt4 ligand, Vascular endothelial growth factor D, VEGF-D, FIGF, VEGFD, c-Fos-induced growth factor
濃度：1 mg/ml
內(nèi)毒素水平：Please contact with the lab for this information.
純度：>95% as determined by SDS-PAGE.
純化方式：Protein A/G purified from cell culture supernatant.
Accession 號：P49767 & O43915
克隆號：Sozinibercept
應(yīng)用：Research Grade Biosimilar
狀態(tài)：Liquid
保存溶液：0.01M PBS, pH 7.4.
穩(wěn)定性和存儲：Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
別名：OPT-302, soluble VEGFR-3, sozinibercept, VGX-300
Biosimilar Candidate CT-P42 in Diabetic Macular Edema: 24-Week Results from a Randomized, Active-Controlled, Phase III Study.PMID:38942386
Risk Factors for Meeting Criteria for Switching from Bevacizumab to Aflibercept When Treating Eyes with Diabetic Macular Edema and Visual Acuity of < 20/40.PMID:38336282
Efficacy and Safety of Faricimab for Macular Edema due to Retinal Vein Occlusion: 24-Week Results from the BALATON and COMINO Trials.PMID:38280653
Faricimab for neovascular age-related macular degeneration and diabetic macular edema: from preclinical studies to phase 3 outcomes.PMID:38847896
Efficacy of Intravitreal Injections Anti-Vascular Endothelial Growth Factor Treatment for Radiation Retinopathy: A Systematic Review and Meta-analysis.PMID:38458409
詳情請咨詢Antibodysystem中國授權(quán)總代理-武漢佰樂博生物技術(shù)有限公司
網(wǎng)址：https://www.biolabreagent.com/product/99/5005.html
武漢佰樂博生物技術(shù)有限公司作為法國Antibodysystem品牌亞洲區(qū)授權(quán)總代理。提供近3萬種蛋白、抗體等核心生命科學(xué)試劑，旨在為生命科學(xué)科研工作者提供專業(yè)、全面、可靠的試劑產(chǎn)品。
試劑 | 耗材 | 定制 | 實驗服務(wù) | 供應(yīng)鏈
免費熱線：027-65279366 /18108604356